Security key
14147L108
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 5,309,425
- Total 13F value
- $7,858,363
- Share change
- -162,340
- Put/Call ratio
- 158%
- SEC-reported price per share
- $1.48
- Number of holders
- 55
- Value change
- -$215,046
- Number of buys
- 13
- Number of sells
- 22
- Shares outstanding
- 66,404,538
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2023
Institutions
55
Top holders
10
CRDF full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
Cardiff Oncology, Inc. SEC filings
Cardiff Oncology, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 14147L108
Recent filing periods:
Ownership snapshot
Top reported holders of CRDF - Cardiff Oncology, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
0/15
Latest evidence
30 Sep 2023
13F
3/4/5
Highest disclosed value: $2,700,656
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
VANGUARD GROUP INC has the largest disclosed position value at $2.7M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD GROUP INC's linked filing trail.
Disclosed position value
Top 5
VANGUARD GROUP INC
$2.7M
Vicki Kelemen
$1.82M
Thomas Adams PhD
$1.24M
Laurion Capital Management LP
$1M
BlackRock Finance, Inc.
$997.5K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$2,700,656
1,942,918 shares
|
— | 30 Sep 2023 |
| Vicki Kelemen |
3/4/5
Exec. VP and COO
|
—
denominator unverified
|
$1,815,590
698,304 shares
|
— | 15 Mar 2023 |
| Thomas Adams PhD |
3/4/5
Former Director
|
—
denominator unverified
|
$1,242,462
477,870 shares
|
— | 10 Jun 2021 |
| Laurion Capital Management LP |
13F
Company
|
—
denominator unverified
|
$1,003,719
722,100 shares
|
— | 30 Sep 2023 |
| BlackRock Finance, Inc. |
13F
Company
|
—
denominator unverified
|
$997,452
717,591 shares
|
— | 30 Sep 2023 |
| Katherine L. Ruffner |
3/4/5
Chief Medical Officer
|
—
denominator unverified
|
$962,042
370,016 shares
|
— | 09 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
55
Shares
5,309,425
Rows available
55
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q3 2023 Across Filers
Q3 2023 holders
55
Q4 2023 holders
55
Holder diff
0
| Investor | Q3 2023 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q3 2023 value | Q4 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend